NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico - Independent Data and Safety Monitoring Board (
DSMB) finds that [b]a single dose of 15 mcg or 45 mcg of H1N1 VLP [/b]is well tolerated and produces a robust immune response - Early data show Novavax's VLP vaccine met the seroconversion and seroprotection criteria recommended by the U.S. and European ...